Hold Rating Maintained as In-Line Results and Improving Margins Offset Near-Term Prescription Headwinds

In a report released yesterday, Mathew Blackman from TD Cowen maintained a Hold rating on Beta Bionics, Inc., with a price target of $16.00.

Mathew Blackman has given his Hold rating due to a combination of factors, including quarterly results and outlook that were broadly in line with prior expectations. Revenue for the quarter matched the company’s earlier preview, and initial 2026 guidance essentially brackets both TD Cowen and broader Street estimates, signaling a fundamentally sound but not clearly undervalued setup at current levels.

He also notes that profitability trends are improving, with gross margins running ahead of forecasts thanks to mix shift toward higher-margin prescription customers and better scale efficiencies. However, commentary on prescription cadence implies near-term consensus for 1Q will likely need to be revised modestly downward, even as the first half of 2026 could see upside, and the pipeline is advancing without new acceleration, leading him to maintain a neutral stance and modestly trim the price target.

Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BBNX in relation to earlier this year.